15 July 2013
Immunocore Limited, the Oxford-based biotechnology company developing novel biological drugs called ImmTACs to treat cancer and viral disease, today announced it has entered into a partnership with GlaxoSmithKline (GSK) for multiple novel targets not addressable using antibody-based technologies. This is Immunocore’s second major partnership this year.
Please click on the link below to download the full Press Release:
Immunocore signs research and licensing agreement with GlaxoSmithKline
